Latest news with #SPRAVATO®
Yahoo
5 days ago
- General
- Yahoo
Relief Mental Health Addresses the Silent Crisis During Men's Mental Health Month
OAK BROOK, lll., June 3, 2025 /PRNewswire/ -- June marks Men's Mental Health Month, a time to raise awareness and reduce stigma around the mental health challenges that men face—often in silence. Relief Mental Health, with 12 outpatient clinics across Colorado, Illinois, New Jersey and Wisconsin, is committed to helping men access personalized, evidence-based care through psychiatry, therapy, and innovative treatments like transcranial magnetic stimulation (TMS), SPRAVATO® (esketamine) and ketamine infusions. The Silent Struggle According to a data brief from the U.S. Centers for Disease Control and Prevention's National Center for Health Statistics (NCHS), nearly 1 in 10 men reported daily feelings of anxiety or depression. However, only about 41 percent of these men took medication for these feelings or had recently talked to a mental health professional. Men are four times more likely than women to die by suicide. Additionally, the American Foundation for Suicide Prevention (AFSP) reports that this accounts for about 70% of all suicide deaths. In Illinois, the suicide rate for men increased by 3.5% from 2020 to 2021, according to the Illinois Department of Public Health. A recent Gallup World Poll analysis found that 25 percent of young U.S. men (ages 15 to 34) reported feeling lonely for much of the prior day, compared to 18 percent of women in the same age group. Treatment that Respects Men's Preferences and Needs At Relief Mental Health, male patients often have the option to work with male providers—something many find more comfortable when opening up about personal issues. Dan Lowder, PA-C, ATC, a psychiatric physician assistant who treats patients as young as 10 at Relief's Orland Park, Ill. clinic, also has a background in athletic training and frequently works with men and adolescent males experiencing sports-related and performance anxiety. "In addition to medication management, I often utilize SPRAVATO®—a nasal spray form of ketamine—for adults with treatment-resistant depression," Lowder explains. "And for men who are hesitant about medications due to side effects—especially sexual dysfunction—TMS therapy can be a game-changer. It doesn't affect the whole body like medications do; it specifically targets the brain regions involved in mood." Why TMS is a Powerful Option for Men TMS is a FDA-cleared, non-invasive treatment for depression, OCD and other diagnoses that uses magnetic pulses to stimulate underactive areas of the brain. Unlike medication, TMS has no systemic side effects, meaning it doesn't impact libido or cause weight gain, sedation, or digestive issues—a concern for many male patients. Relief Mental Health offers TMS therapy at all of its locations, along with psychiatric evaluation, medication management, therapy, and SPRAVATO® treatment. With a multidisciplinary team across four states, Relief ensures that men from all walks of life can find effective, personalized mental health care. For more information about Relief Mental Health or to schedule a consultation for any of its services, individuals can call 855.205.4764, email info@ or visit About Relief Mental Health Relief Mental Health is a leading outpatient provider of transcranial magnetic stimulation (TMS), SPRAVATO® (esketamine), IV ketamine, psychiatry, and therapy, for the treatment of depression, obsessive-compulsive disorder, anxiety and other diagnoses. Founded in January 2020 and dedicated to delivering expedited care, Relief aims to create a new standard for mental health care, offering a continuum of innovative therapeutic interventions and responding to evolving patient needs. For more information, visit CONTACT: Melanie EilersChief Marketing Officermelanie@ View original content to download multimedia: SOURCE Relief Mental Health Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- General
- Yahoo
Relief Mental Health Addresses the Silent Crisis During Men's Mental Health Month
OAK BROOK, lll., June 3, 2025 /PRNewswire/ -- June marks Men's Mental Health Month, a time to raise awareness and reduce stigma around the mental health challenges that men face—often in silence. Relief Mental Health, with 12 outpatient clinics across Colorado, Illinois, New Jersey and Wisconsin, is committed to helping men access personalized, evidence-based care through psychiatry, therapy, and innovative treatments like transcranial magnetic stimulation (TMS), SPRAVATO® (esketamine) and ketamine infusions. The Silent Struggle According to a data brief from the U.S. Centers for Disease Control and Prevention's National Center for Health Statistics (NCHS), nearly 1 in 10 men reported daily feelings of anxiety or depression. However, only about 41 percent of these men took medication for these feelings or had recently talked to a mental health professional. Men are four times more likely than women to die by suicide. Additionally, the American Foundation for Suicide Prevention (AFSP) reports that this accounts for about 70% of all suicide deaths. In Illinois, the suicide rate for men increased by 3.5% from 2020 to 2021, according to the Illinois Department of Public Health. A recent Gallup World Poll analysis found that 25 percent of young U.S. men (ages 15 to 34) reported feeling lonely for much of the prior day, compared to 18 percent of women in the same age group. Treatment that Respects Men's Preferences and Needs At Relief Mental Health, male patients often have the option to work with male providers—something many find more comfortable when opening up about personal issues. Dan Lowder, PA-C, ATC, a psychiatric physician assistant who treats patients as young as 10 at Relief's Orland Park, Ill. clinic, also has a background in athletic training and frequently works with men and adolescent males experiencing sports-related and performance anxiety. "In addition to medication management, I often utilize SPRAVATO®—a nasal spray form of ketamine—for adults with treatment-resistant depression," Lowder explains. "And for men who are hesitant about medications due to side effects—especially sexual dysfunction—TMS therapy can be a game-changer. It doesn't affect the whole body like medications do; it specifically targets the brain regions involved in mood." Why TMS is a Powerful Option for Men TMS is a FDA-cleared, non-invasive treatment for depression, OCD and other diagnoses that uses magnetic pulses to stimulate underactive areas of the brain. Unlike medication, TMS has no systemic side effects, meaning it doesn't impact libido or cause weight gain, sedation, or digestive issues—a concern for many male patients. Relief Mental Health offers TMS therapy at all of its locations, along with psychiatric evaluation, medication management, therapy, and SPRAVATO® treatment. With a multidisciplinary team across four states, Relief ensures that men from all walks of life can find effective, personalized mental health care. For more information about Relief Mental Health or to schedule a consultation for any of its services, individuals can call 855.205.4764, email info@ or visit About Relief Mental Health Relief Mental Health is a leading outpatient provider of transcranial magnetic stimulation (TMS), SPRAVATO® (esketamine), IV ketamine, psychiatry, and therapy, for the treatment of depression, obsessive-compulsive disorder, anxiety and other diagnoses. Founded in January 2020 and dedicated to delivering expedited care, Relief aims to create a new standard for mental health care, offering a continuum of innovative therapeutic interventions and responding to evolving patient needs. For more information, visit CONTACT: Melanie EilersChief Marketing Officermelanie@ View original content to download multimedia: SOURCE Relief Mental Health Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinic Combined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizations Topline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S. The all-share transaction is expected to close in the second half of 2025 Concurrent $30.0M private placement by Ferring Ventures S.A. and Adage Capital Partners LP Conference call scheduled for 8:00am EDT today NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ('atai' or 'Company'), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited ('Beckley'), a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today announced a definitive agreement under which atai and Beckley plan to combine in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase 2b success criteria. 'The strategic combination marks a transformational moment, solidifying us as a leader in rapid-acting and accessible psychedelic treatments for mental health conditions with a pipeline of potential first-in-class and best-in-class assets,' stated Srinivas Rao, M.D., Ph.D., Chief Executive Officer and Co-Founder of atai. 'With a unified vision and a synergistic pipeline, we believe we are well-positioned to unlock the strategic value of our clinical development programs for both patients and shareholders. Together, we plan to move confidently towards our goal of bringing innovative interventional psychiatry therapies to patients in need of new treatments.' Cosmo Feilding Mellen, Chief Executive Officer and Co-Founder of Beckley added, 'This combination brings together two highly complementary pipelines to create a market leader at the forefront of psychiatric care. Clinical data has shown the rapid and durable effects of our compounds, as well as their potential to fit within the existing treatment paradigm established by SPRAVATO®. We believe that the unified business will be even better positioned to accelerate development, drive long-term value for shareholders, and - most importantly - deliver meaningful innovation for patients.' 'This transaction marks a pivotal milestone in delivering on the strategic vision we set forth from the start of atai in 2018: to be the leader in the psychedelic space,' added Christian Angermayer, Co-Founder and Chairman of atai. 'I am also very pleased to announce the concurrent financing with existing investors from both companies. The continued support from Ferring Ventures, a valued investor in atai, and Adage Capital, a longstanding investor in Beckley, further validates the strength and potential of this combination.' Transaction Benefits Market-Leading Pipeline: atai Beckley will boast a synergistic fully owned pipeline that includes proprietary, rapid-acting psychedelic compounds differentiated by their convenient route of administration and short time-in-clinic. Near-Term Clinical Milestones: Topline data from the eight-week, randomized core stage of Beckley's BPL-003 Phase 2b trial in treatment-resistant depression (NCT05870540) is expected in mid-2025, representing a potentially significant value inflection point. The study builds on previously reported open-label results which demonstrated that a single dose of BPL-003, when given as a monotherapy or alongside SSRIs, was well-tolerated and could produce a rapid and lasting antidepressant effect for up to three months. Financial Synergies and Strong IP Portfolio: Cash runway through multiple Phase 2 clinical catalysts, near and long-term operational synergies, as well as a strong IP portfolio with granted U.S. patents out to 2043. Unified Vision and Team: The new entity is expected to leverage the expertise, teams, and networks of both organizations to accelerate the development and commercialization of transformative mental health treatments. Transaction Termsatai made a strategic investment in Beckley in January 2024. Under the terms of the deal, Beckley's shareholders (other than atai) will be issued approximately 105 million new shares as consideration for the remaining shares of Beckley not presently held by atai. These newly issued shares equate to approximately 31% of the combined company on a fully diluted basis, based on the treasury stock method, upon closing of the transaction and the concurrent private placement, and value Beckley at approximately $390 million. These newly issued atai shares are subject to a lock-up wherein, following the completion of the lock-up period, 1/12 of the shares are released every month. Additionally, Apeiron Investment Group, the family office of Mr. Angermayer, voluntarily entered into a similar lock-up agreement covering all of its shares in atai. Beckley also intends to distribute Eleusis Holdings Limited and its subsidiaries, which hold assets and funding related to its second clinical-stage asset, ELE-101, out of Beckley prior to closing of the transaction. Timing and Approvalsatai's Supervisory Board and Management Board and Beckley's Board of Directors have approved the transaction. The transaction is expected to close in the second half of 2025, subject to approval of the share issuance by the shareholders of atai and satisfaction of other customary closing conditions. Concurrent FinancingConcurrent with the transaction, atai also executed a $30.0 million private placement with Ferring Ventures S.A. and Adage Capital Partners LP. This financing is not contingent on closing of the transaction. The private placement is expected to close on June 3, 2025, subject to customary closing conditions. The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or any state's securities laws, and will be issued and sold in a private placement in reliance on Section 4(a)(2) of the Securities Act. The securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. atai granted registration rights to the purchasers in the private placement, and has agreed to file a registration statement with the Securities and Exchange Commission (the 'SEC') registering the resale of the common shares issued in the private placement and the shares of common stock issuable upon exercise of the pre-funded warrants issued in the private placement. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Conference Callatai and Beckley will host a conference call and live webcast today Monday, June 2, 2025 at 8:00 a.m. EDT. The conference call can be accessed by dialing 1-800-715-9871 for participants in the U.S. and 1-646-307-1963 for international callers, with the Conference ID: 1459387. The webcast can be accessed on the Investors section of atai's corporate website under Events. The presentation and an archived replay of the webcast will be available in the same section of the website for a minimum of 30 days following the event. AdvisorsGuggenheim Securities is serving as financial advisor to atai and Latham & Watkins LLP is serving as its legal counsel. Cantor is serving as financial advisor to Beckley, and CMS and Mayer Brown are serving as its legal counsel. Guggenheim Securities is acting as the lead placement agent for the private placement. Berenberg is acting as joint-lead placement agent for the private placement. About atai Life Sciencesatai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. atai's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. They are also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about atai's mission, visit or follow the Company on LinkedIn and on X. About Beckley Psytech Beckley Psytech Ltd is a private biopharmaceutical company dedicated to improving the lives of people living with neuropsychiatric disorders by developing rapid-acting psychedelic medicines. Founded in 2019, and underpinned by more than two decades of pioneering scientific research from the Beckley Foundation, Beckley Psytech combines world-leading psychedelic science with extensive drug development expertise in order to optimise patient outcomes, improve treatment opportunities and ease the burden neuropsychiatric conditions have on individuals, healthcare systems and society. For more information about Beckley Psytech, visit or follow the Company on LinkedIn. About BPL-003BPL-003 is Beckley Psytech's patent-protected, proprietary intranasal formulation of mebufotenin benzoate, administered via a nasal spray device used in a previously approved drug product. BPL-003 is designed to deliver rapid and durable effects from a single dose, with a short time in the clinic, and is being investigated as a potential therapy for treatment resistant depression (TRD) and for alcohol use disorder (AUD). BPL-003 is covered by granted US, UK and European composition-of-matter patents, with multiple further claims pending in various jurisdictions. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). The words 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'anticipate,' 'initiate,' 'could,' 'would,' 'project,' 'plan,' 'potentially,' 'preliminary,' 'likely,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: expectations regarding the closing of the transaction, including timing and approvals; expectations regarding operations of the combined company, including strategic value of the clinical development programs for patients and shareholders as well as expectations regarding financial synergies; timing and results of Beckley's BPL-003 Phase 2b trial and related data readouts; expectations regarding Beckley's other clinical assets, including ELE-101; expectations regarding the concurrent private placement, including related closing conditions; our business strategy and plans; and the potential, success, cost and timing of development of our product candidates, and the product candidates of those companies we invest in. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled 'Risk Factors' in our most recent Annual Report on Form 10-K filed with the SEC, as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law. No Offer or Solicitation This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. Additional Information and Where to Find It This press release is being made in respect of the proposed transaction between the Company and Beckley Psytech Limited. In connection with the proposed transaction, the Company will file with the SEC a proxy statement on Schedule 14A (the 'Proxy Statement'), as well as other relevant documents regarding the proposed transaction. This press release is not a substitute for the Proxy Statement or any other document which the Company may file with the SEC. INVESTORS ARE URGED TO READ IN THEIR ENTIRETY THE PROXY STATEMENT REGARDING THE TRANSACTION WHEN IT BECOMES AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. A free copy of the Proxy Statement, as well as other filings containing information about the Company, when such documents become available, may be obtained at the SEC's website ( Participants in the Solicitation The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from its shareholders in respect of the proposed transactions contemplated by the Proxy Statement. Information regarding the persons who are, under the rules of the SEC, participants in the solicitation of the shareholders of the Company in connection with the proposed transactions, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the Proxy Statement when it is filed with the SEC. Information regarding the Company's directors and executive officers is contained in its Annual Report on Form 10-K for the year ended December 31, 2024 and its Proxy Statement on Schedule 14A, dated April 21, 2025, which are filed with the SEC. Contact InformationInvestor Contact:IR@ Media Contact:PR@ Beckley media contact: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-04-2025
- Health
- Yahoo
April is Counseling Awareness Month: Spotlighting the Power of Psychotherapy and Innovative Mental Health Treatments
When Therapy Alone Isn't Enough, Options Like TMS and SPRAVATO® Provide Additional Relief OAK BROOK, Ill., April 8, 2025 /PRNewswire/ -- As we honor Counseling Awareness Month, Relief Mental Health recognizes the critical role that therapy plays in helping individuals navigate mental health challenges and build a life worth living. This month is a time to elevate the importance of psychotherapy, reduce stigma, and educate the public on how comprehensive mental health care can truly transform lives. Psychotherapy, also known as talk therapy, is a cornerstone of mental health treatment. At Relief Mental Health, clinicians use evidence-based modalities like cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and exposure and response prevention (ERP), to help clients work through anxiety, depression, trauma, OCD, and more. These therapies help people identify unhelpful patterns, build coping strategies, and improve emotional regulation. "Therapy provides a safe space for people to explore their thoughts, emotions, and behaviors, while learning new ways to respond to life's stressors," says Callie Oetking, LCSW, clinical director at Relief Mental Health. "But for some individuals, therapy alone may not be enough. That's why it's so important we offer a full spectrum of treatment options." For those who need additional support, Relief Mental Health offers psychiatric medication management, transcranial magnetic stimulation (TMS), SPRAVATO® (esketamine), and ketamine infusions: Psychiatric medication can help rebalance brain chemistry and reduce symptoms of mood, anxiety, and thought disorders. However, studies show that approximately 30 percent of individuals with depression either do not respond to antidepressant medications or cannot tolerate their side effects. For those patients, alternative treatments can make a life-changing difference. That's why Relief offers innovative options like TMS, SPRAVATO®, and IV ketamine—nontraditional approaches proven to help when other treatments fall short. TMS therapy is a non-invasive, drug-free treatment that uses magnetic pulses to stimulate areas of the brain associated with mood regulation. It's FDA-cleared for depression, OCD, and other diagnoses, and patients remain awake and alert throughout each session. SPRAVATO®, a nasal spray form of ketamine, is FDA-approved for treatment-resistant depression or major depression with suicidal thoughts or behaviors. Administered under medical supervision, it offers fast-acting symptom relief for those who haven't found success with traditional antidepressants. IV ketamine provides rapid symptom relief for PTSD, anxiety, bipolar depression, and more, and is often life-changing for those in crisis. "While each treatment has its own benefits, the real magic happens when these approaches are combined with psychotherapy," adds Oetking. "We see the most meaningful and lasting improvements when patients engage in therapy alongside medication, TMS, or ketamine-based treatments. It's a whole-person approach that promotes both healing and growth." For more information about Relief Mental Health or to schedule a consultation for any of its services, individuals can call 855.205.4764, email info@ or visit About Relief Mental Health Relief Mental Health is an award-winning outpatient provider of transcranial magnetic stimulation (TMS), psychedelics (SPRAVATO® esketamine and IV ketamine), psychiatry, and therapy, for the treatment of depression, obsessive-compulsive disorder, anxiety and other diagnoses. Founded in January 2020 and dedicated to delivering expedited care, Relief has 11 facilities in three states. In Illinois, clinics are located in Chicago (Lakeview and West Loop), Oak Brook, Orland Park, Northbrook, Rockford, and St. Charles. Relief's other clinics are in Warren and Red Bank, New Jersey, and Middleton and West Allis, Wisconsin. Relief aims to create a new standard for mental health care, offering a continuum of innovative therapeutic interventions and responding to evolving patient needs. For more information, visit CONTACT: Melanie EilersChief Marketing Officermelanie@ View original content to download multimedia: SOURCE Relief Mental Health Sign in to access your portfolio
Yahoo
04-03-2025
- Health
- Yahoo
Relief Mental Health Honored as Emerging Business of the Year by Northbrook Chamber of Commerce
NORTHBROOK, Ill., March 4, 2025 /PRNewswire/ -- Relief Mental Health, a leading outpatient provider of mental health treatment, is proud to announce its recognition as the Emerging Business of the Year by the Northbrook Chamber of Commerce. Founded by Susan Mueller, CEO, Relief Mental Health first opened its doors in Oak Brook, Ill., in January 2020—just before the onset of the pandemic—followed by a clinic in Northbrook in September that year. Since then, the organization has expanded to 11 clinics across three states, demonstrating its commitment to delivering innovative and accessible mental health care. At the forefront of Relief Mental Health's offerings is transcranial magnetic stimulation (TMS), a non-invasive, FDA-approved therapy for depression, OCD and other diagnoses that utilizes magnetic pulses to stimulate specific areas of the brain associated with mood regulation. TMS is covered by insurance, produces no systemic side effects, and is effective in treating patients whose symptoms have not improved with routine treatments like medications and therapy. In addition to TMS, Relief Mental Health provides SPRAVATO® (esketamine) nasal spray, an FDA-approved medication for adults with treatment-resistant depression or depression accompanied by suicidal thoughts or behaviors. A form of ketamine, SPRAVATO® works differently than traditional antidepressants by restoring the balance of certain neurotransmitters in the brain, providing rapid relief from depressive symptoms. When used in combination with TMS therapy, patients may experience both immediate and sustained improvements in their mental health. Recognizing the importance of a comprehensive approach to mental health, Relief Mental Health integrates psychiatric medication management and therapy into personalized treatment plans. This holistic strategy ensures that each patient receives tailored care, addressing their unique needs and promoting long-term well-being. Unlike many psychiatric providers with long waitlists, Relief Mental Health prioritizes expedited access to care—getting patients seen within a week, or even days, of their initial call. "Timely intervention is crucial for individuals struggling with depression, anxiety, OCD, and other mental health diagnoses," said Mueller. "By eliminating barriers to treatment, we ensure that those in need receive help when they need it most." The treatment team at Relief's Northbrook clinic includes Teresa Poprawski, MD, neuropsychiatrist and chief medical officer; Anna Hereth, PA-C, CAQ-PSYCH, psychiatric physician assistant; Caroline Onischak, APRN, PMHNP-BC, psychiatric nurse practitioner; Susan Anewalt, LPC, CADC, therapist; and Julia Cleary, clinic manager and certified TMS technician. Their collective expertise and delivery of personalized care have been instrumental in the clinic's success and recognition within the community. Relief Mental Health will officially accept the Emerging Business of the Year award in person at the Northbrook Chamber's Annual Meeting and Awards Dinner on March 31. Relief's Northbrook clinic is located at 899 Skokie Blvd., Suite 260. For more information about Relief Mental Health and its services, please visit call 855.205.4764 or email info@ About Relief Mental Health Relief Mental Health is a leading outpatient provider of transcranial magnetic stimulation (TMS), psychedelics (SPRAVATO® esketamine and IV ketamine), psychiatry, and therapy, for the treatment of depression, obsessive-compulsive disorder, anxiety and other diagnoses. Founded in January 2020 and dedicated to delivering expedited care, Relief has 11 facilities in three states. In Illinois, clinics are located in Chicago (Lakeview and West Loop), Oak Brook, Orland Park, Northbrook, Rockford, and St. Charles. Relief's other clinics are in Warren and Red Bank, New Jersey, and Middleton and West Allis, Wisconsin. Relief aims to create a new standard for mental health care, offering a continuum of innovative therapeutic interventions and responding to evolving patient needs. For more information, visit CONTACT: Melanie EilersChief Marketing Officermelanie@ View original content to download multimedia: SOURCE Relief Mental Health
